Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-07-01
2008-07-01
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800, C530S330000, C530S327000, C600S557000
Reexamination Certificate
active
07393835
ABSTRACT:
PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating diseases states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described.
REFERENCES:
patent: 4351829 (1982-09-01), Zetler et al.
patent: 5776685 (1998-07-01), Riedel
patent: 5783405 (1998-07-01), Mochly-Rosen et al.
patent: 5935803 (1999-08-01), Vasquez et al.
patent: 6165977 (2000-12-01), Mochly-Rosen
patent: 6376467 (2002-04-01), Messing et al.
patent: 6395306 (2002-05-01), Cui et al.
patent: 2003/0223981 (2003-12-01), Mochly-Rosen et al.
patent: 2004/0009922 (2004-01-01), Mochly-Rosen
patent: WO 94/04686 (1994-03-01), None
patent: WO 97/14038 (1997-04-01), None
patent: WO 99/43805 (1999-09-01), None
patent: WO 00/01415 (2000-01-01), None
patent: WO 00/53218 (2000-09-01), None
patent: WO 01/46252 (2001-06-01), None
patent: WO 01/75067 (2001-10-01), None
The Journal of Biological Chemistry, 2001, 276, 29644-29650.
Stebbins, et al., The Journal of Biological chemistry, 2001, 276, 29644-29650.
Chen, et al., PNAS, 2001, 98, 11114-11119.
Chen, L., et al.,PNAS98(20):11114-11119, (2001).
Julius, D. and Basbaum, A.I.,Nature, 413:203-210, (2001).
Igwe, O.J. and Chronwall, B.M.,Neuroscience104(3):875-890, (2001).
Martin, W.J., et al.,Neuroscience88(4):1267-1274, (1999).
Martin, W.J., et al.,The Journal of Neuroscience21(14):5321-5327, (2001).
Petersen-Zeitz, K.R. and Basbaum, A.I.,Pain Supplement6:S5-S12, (1999).
Stebbins, E.G. and Mochly-Rosen, D.,J of Biological Chemistry276(32):29644-29650, (2001).
Wen, Z.H., et al.,Neuroscience Letters309:25-28, (2001).
Falnes, P.O., et al.,Biochemistry40:4349-4358, (2001).
Jones, P.F., et al.,Cell Regulation2:1001-1009, (1991).
Meier, R., et al.,The Journal of Biological Chemistry272(48):30491-30497, (1997).
Aley, K. et al.,The Journal of Neuroscience20(12):4680-4685, 2000.
Dina, O. et al.,The Journal of Neuroscience20(22):8614-8619, 2000.
Csukai et al.,Pharmacological Research, 39(4):253-259 (1999).
Knopf et al.,Cell, 46:491-502 (1986).
Kubo et al.,FEBS Letters, 223(1):138-142 (1987).
Malmberg et al.,Science, 278:279-283 (1997).
Mochly-Rosen et al.,FASEB Journal, 12:35-42 (1998).
Ono et al.,Science, 236:1116-1120 (1987).
Gokmen-Polar et al., “Mapping of a Molecular determinant for Protien Kinase C Betall Isozyme Function”,The Journal of Biological Chemistry, 273(32):20261-20266 (1998).
Chen, L. et al.,Chemistry&Biology, 8:1123-1129 (2001).
Sweitzer et al., “Developmental Regulation of Inflammatory Pain by Protein Kinase C”, Society for Neuroscience Abstract Viewer and Itinerary Planner, 32ndAnnual Meeting of the Society of Neuroscience (2002).
Gupta Anish
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Peptide inhibitors of protein kinase C does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide inhibitors of protein kinase C, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide inhibitors of protein kinase C will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2770113